NanoViricides (NYSE:NNVC) Upgraded by StockNews.com to Hold

NanoViricides (NYSE:NNVC) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Friday.

NanoViricides Trading Up 0.3 %

NYSE:NNVC traded up $0.01 during mid-day trading on Friday, hitting $1.50. The company had a trading volume of 107,234 shares, compared to its average volume of 181,020. The business has a fifty day simple moving average of $1.61 and a 200-day simple moving average of $1.79. NanoViricides has a 1 year low of $1.00 and a 1 year high of $3.59. The firm has a market capitalization of $20.86 million, a price-to-earnings ratio of -2.14 and a beta of 0.94.

NanoViricides (NYSE:NNVC) last announced its earnings results on Friday, September 27th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01.

Institutional Trading of NanoViricides

A hedge fund recently raised its stake in NanoViricides stock. Renaissance Technologies LLC boosted its position in NanoViricides, Inc. (NYSE:NNVC) by 20.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 102,100 shares of the company’s stock after buying an additional 17,600 shares during the quarter. Renaissance Technologies LLC owned approximately 0.86% of NanoViricides worth $176,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.30% of the company’s stock.

About NanoViricides

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.